It targets three incretin and metabolic hormone receptors simultaneously the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
The government is even getting in on the action with the recent launch of TrumpRx
This gut hormone has many important metabolic actions, including: The effectiveness and safety of Wegovy have been demonstrated in the Semaglutide Treatment Effect for People with Obesity (STEP) program
Studies of orforglipron (Foundayo) showed significant and sustained weight loss (at least 10% of starting weight) over 72 weeks
Proposed mechanisms include reduced inflammation, improved endothelial function, decreased blood pressure, improved lipid profiles, and direct cardioprotective effects via GLP-1 receptors expressed on cardiomyocytes
Maintain or increase exercise volume